SEC Form 4 · accession 0001209191-16-155989
Intra-Cellular Therapies, Inc. · ITCI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kimberly E. Vanover
Officer — SVP, Clinical Development
Period of report
Dec 15, 2016
Accepted (ET)
Dec 19, 2016 · 5:50 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001567514
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Dec 15, 2016 | M | 5,000 | $1.36 | A | 5,000 | D | |
| Common StockF2,F3 | Dec 15, 2016 | S | 2,500 | $15.2622 | D | 2,500 | D | |
| Common StockF4 | Dec 15, 2016 | M | 10,000 | $1.50 | A | 12,500 | D | |
| Common StockF4,F5 | Dec 15, 2016 | S | 5,000 | $15.1946 | D | 7,500 | D | |
| Common StockF6 | Dec 15, 2016 | M | 3,750 | $1.50 | A | 11,250 | D | |
| Common StockF6,F7 | Dec 15, 2016 | S | 1,875 | $15.277 | D | 9,375 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F8 | $1.36 | Dec 15, 2016 | M | 5,000 | D | — | Apr 11, 2017 | Common Stock | 5,000 | 0 | D |
| Stock Option (right to buy)F8 | $1.50 | Dec 15, 2016 | M | 10,000 | D | — | Dec 12, 2017 | Common Stock | 10,000 | 0 | D |
| Stock Option (right to buy)F8 | $1.50 | Dec 15, 2016 | M | 3,750 | D | — | Dec 18, 2018 | Common Stock | 3,750 | 0 | D |
Explanation of responses
- F1All exercises of options and sales of shares reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 7, 2016.
- F2This Form 4 reports the exercise of an option to purchase 5,000 shares of the Issuer's common stock that was to expire on April 11, 2017, and a sale of an aggregate of 2,500 of such shares primarily to cover the reporting person's tax liability.
- F3The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.09 to $15.39, inclusive. The reporting person undertakes to provide Intra-Cellular Therapies, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3), (5) and (7) to this Form 4.
- F4This Form 4 reports the exercise of an option to purchase 10,000 shares of the Issuer's common stock that was to expire on December 12, 2017, and a sale of an aggregate of 5,000 of such shares primarily to cover the reporting person's tax liability.
- F5The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.09 to $15.39, inclusive.
- F6This Form 4 reports the exercise of an option to purchase 3,750 shares of the Issuer's common stock that was to expire on December 18, 2018, and a sale of an aggregate of 1,875 of such shares primarily to cover the reporting person's tax liability.
- F7The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.12 to $15.39, inclusive.
- F8All shares underlying this option have vested.